Author:
Carrossini N.,Meireles Da Costa N.,Andrade-Barreto E.,Sousa V. P. L.,Nicolau-Neto P.,Souza-Santos P. T.,Mansur G. R.,Wernersbach L.,Bozza P. T.,Viola J. P. B.,Ribeiro Pinto Luis Felipe
Abstract
AbstractEsophageal cancer (EC) is an aggressive disease, presenting two main histological subtypes: adenocarcinoma (EAC) and squamous cell carcinoma (ESCC). The two EC subtypes widely differ concerning virtually all factors. ESCC development is mainly associated with tobacco and alcohol abuse, whereas obesity and chronic gastroesophageal reflux disease (GERD) are important risk factors not only for EAC, but also for for Barrett’s esophagus (BE), an intestinal metaplasia that precedes EAC. Obesity triggers ectopic lipid droplets (LD) accumulation in non-adipose tissues. LD are organelles involved in cell metabolism, signaling, proliferation and production of inflammatory mediators. Therefore, the aim of this work was to investigate LD occurrence and role in EC. This study shows progressive LD levels increase along EAC development, in esophageal samples from non-obese through obese individuals, as well as BE, and EAC patients, whereas no significant changes were observed in ESCC samples, when compared to non-tumor samples. Additionally, in order to mimic BE and EAC risk factors exposure, a non-tumor esophageal cell line was incubated with oleic acid (OA) and acidified medium and/or deoxycholic acid (DCA), revealing a significant increment in LD amount as well as in COX-2 and CXCL-8 expression, and in IL-8 secretion. Further, COX-2 expression and LD amount presented a significant positive correlation and were detected co-localized in EAC, but not in ESCC, suggesting that LD may be the site for eicosanoid production in EAC. In conclusion, this study shows that obesity, and BE- and EAC-associated inflammatory stimuli result in a gradual increase of LD, that may be responsible for orchestrating inflammatory mediators’ production and/or action, thus contributing to BE and EAC genesis and progression.
Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. Bray, F. et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
2. Pennathur, A., Gibson, M. K., Jobe, B. A. & Luketich, J. D. Oesophageal carcinoma. Lancet 381, 400–412 (2013).
3. Blot, W. J., McLaughlin, J. K. & Fraumeni, J. F. Esophageal cancer. In Cancer Epidemiology and Prevention (eds Schottenfeld, D. & Fraumeni, J. F.) 579–602 (Oxford University Press, New York, 2006).
4. Coleman, H. G., Xie, S. H. & Lagergren, J. The epidemiology of esophageal adenocarcinoma. Gastroenterology 154, 390–405 (2018).
5. Schoofs, N., Bisschops, R. & Prenen, H. Progression of Barrett’s esophagus toward esophageal adenocarcinoma: An overview. Ann. Gastroenterol. 30, 1–6 (2017).